Chrystene Nguyen, MD
Family Medicine · Costa Mesa, CANPI 1710123609
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 49 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,240 and has fallen 97.5% since, to $31 in 2025. Among family medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 49 payments — averaging $79.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$615
- Gilead$591
- Lilly USA, LLC$403
- Amgen$366
- Regeneron Healthcare Solutions, Inc.$362
- GSK$278
- plus $1K from 17 others
What the payments were for
- Travel & lodging$20%
- Food & beverage$3,876100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 6 | $615 |
| Gilead | 5 | $591 |
| Lilly USA, LLC | 6 | $403 |
| Amgen | 3 | $366 |
| Regeneron Healthcare Solutions, Inc. | 3 | $362 |
| GSK | 4 | $278 |
| Nevro Corp. | 1 | $176 |
| Sanofi | 2 | $174 |
| Abiomed | 2 | $153 |
| Genentech USA, Inc. | 1 | $131 |
| UCB, Inc. | 1 | $125 |
| Phathom Pharmaceuticals, Inc. | 1 | $125 |
| Endogastric Solutions, Inc | 1 | $116 |
| Johnson & Johnson | 1 | $50 |
| Vifor Pharma, Inc. | 2 | $35 |
| Boehringer Ingelheim | 2 | $32 |
| Novo Nordisk | 2 | $31 |
| United Therapeutics Corporation | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Grifols USA, LLC | 1 | $21 |
| ZOLL Respicardia, Inc. | 1 | $17 |
| Exact Sciences | 1 | $15 |
| Philips North America LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,878 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $240 |
| Atorvastatin Calcium | 11 | $51 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 12 | $30 |
| Cephalexin | 11 | $28 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Costa Mesa
- Sherly SoleimanEncino$1.2M
- Pamela KushnerLos Angeles$1.2M
- Sujata NarayanStanford$1.2M
- Jeffrey UngerChino$906K
- Alexander RivkinLos Angeles$866K
- Scott HowellLos Angeles$793K
- Derrick ButlerLos Angeles$692K
- Sandra CalmanMontara$589K
- Anthony JonesOakland$377K
- Amira AyadBakersfield$360K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.